http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5972365-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97ddd4d1d0ebc8a7d2c8e7d214d08cf3
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
filingDate 1996-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 1999-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9e90f4591352d28b6455891f2fd7609
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdf06c6f4813a04af3b9f076ca087966
publicationDate 1999-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-5972365-A
titleOfInvention Remedy for prurigo
abstract As a remedy for prurigo, IFN- gamma is administered systemically, preferably intravenously and still preferably via drip infusion, in a daily dose of from 250,000 JRU to 4,000,000 JRU preferably once a day or in several portions depending on the conditions of the patient and side effects. The administration method and dose can be changed depending on the conditions, age, etc., of the patient. IFN- gamma is highly effective in the treatment of prurigo. The action of IFN- gamma to normalize the imbalance in peripheral lymphocytes is suggested as the mechanism for the efficacy of IFN- gamma in the treatment of prurigo.
priorityDate 1995-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9107984-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0254593-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9320108-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0177910-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5200177-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398680
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226420034
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393795
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5281068
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66577194
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16533
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398678
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53690141
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398679
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5715230
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396260
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4615
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127486604
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135774423
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226416055
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136014646
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID716121
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12807688
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226420033

Total number of triples: 40.